These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9926100)

  • 1. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.
    Travis MJ; Busatto GF; Pilowsky LS; Mulligan R; Acton PD; Gacinovic S; Mertens J; Terrière D; Costa DC; Ell PJ; Kerwin RW
    Br J Psychiatry; 1998 Sep; 173():236-41. PubMed ID: 9926100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study.
    Jones HM; Travis MJ; Mulligan R; Bressan RA; Visvikis D; Gacinovic S; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2001 Aug; 157(1):60-6. PubMed ID: 11512044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.
    Trichard C; Paillère-Martinot ML; Attar-Levy D; Recassens C; Monnet F; Martinot JL
    Am J Psychiatry; 1998 Apr; 155(4):505-8. PubMed ID: 9545996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects.
    Baeken C; D'haenen H; Flamen P; Mertens J; Terriere D; Chavatte K; Boumon R; Bossuyt A
    Eur J Nucl Med; 1998 Dec; 25(12):1617-22. PubMed ID: 9871092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S
    Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects.
    Busatto GF; Pilowsky LS; Costa DC; Mertens J; Terriere D; Ell PJ; Mulligan R; Travis MJ; Leysen JE; Lui D; Gacinovic S; Waddington W; Lingford-Hughes A; Kerwin RW
    Eur J Nucl Med; 1997 Feb; 24(2):119-24. PubMed ID: 9021107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study.
    Lavalaye J; Booij J; Linszen DH; Reneman L; van Royen EA
    Psychopharmacology (Berl); 2001 Jun; 156(1):53-7. PubMed ID: 11465633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.
    Bressan RA; Erlandsson K; Stone JM; Mulligan RS; Krystal JH; Ell PJ; Pilowsky LS
    Biol Psychiatry; 2005 Jul; 58(1):41-6. PubMed ID: 15992521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.
    Goyer PF; Berridge MS; Morris ED; Semple WE; Compton-Toth BA; Schulz SC; Wong DF; Miraldi F; Meltzer HY
    J Nucl Med; 1996 Jul; 37(7):1122-7. PubMed ID: 8965181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.
    Schreiber R; Brocco M; Millan MJ
    Eur J Pharmacol; 1994 Oct; 264(1):99-102. PubMed ID: 7530204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo 5-HT
    Radhakrishnan R; Matuskey D; Nabulsi N; Gaiser E; Gallezot JD; Henry S; Planeta B; Lin SF; Ropchan J; Huang Y; Carson RE; D'Souza DC
    Psychiatry Res Neuroimaging; 2020 Jan; 295():111007. PubMed ID: 31760336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.